The inhibitory action of fatty acids on DNA polymerase beta.

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

The inhibitory action of fatty acids on DNA polymerase beta.

Biochim Biophys Acta. 1997 Oct 20;1336(3):509-21. Unique Identifier : AIDSLINE MED/98033001
Mizushina Y; Yoshida S; Matsukage A; Sakaguchi K; Department of Applied Biological Science, Faculty of Science and; Technology, Science University of Tokyo, Japan.

Abstract: We found previously that long-chain fatty acids could inhibit eukaryotic DNA polymerase activities in vitro [1,2]. The purpose of the present study was to investigate the mode of this inhibition in greater detail. Among the C18 to C24 fatty acids examined, the strongest inhibitor was a C24 fatty acid, nervonic acid (NA), and the weakest was a C18 fatty acid, linoleic acid (LA). We analyzed the inhibitory effect of these two fatty acids and their modes of action. For DNA polymerase beta (pol. beta), NA acted by competing with both the substrate- and template-primer, but for DNA polymerase alpha (pol. alpha) or human immunodeficiency virus type 1 reverse transcriptase (HIV-1 reverse transcriptase or HIV-RT), NA acted non-competitively. NA-binding to pol. beta could be stopped with a non-ionic detergent, but the binding to pol. alpha or HIV-RT could not. The inhibition mode of LA showed the same characteristics, except that the minimum inhibitory dose of the longer chain was much lower. We also tested the effects of NA and LA using pol. beta and its proteolytic fragments, as described by Kumar et al. [3,4]. Both of the fatty acids were found to bind to the 8 kDa DNA-binding domain fragment, and to suppress binding to the template-primer DNA. We found that 10,000 times more of either fatty acid was required for it to bind to the 31 kDa catalytic domain or inhibit the DNA polymerase activity. The possible modes of inhibition by these long-chain fatty acids are discussed, based on the present findings.

Keywords: Animal Cattle Comparative Study DNA/BIOSYNTHESIS DNA Polymerase beta/*ANTAGONISTS & INHIB/METABOLISM DNA Polymerase I/ANTAGONISTS & INHIB/METABOLISM Enzyme Inhibitors Fatty Acids, Monounsaturated/PHARMACOLOGY Fatty Acids, Nonesterified/*PHARMACOLOGY Fatty Acids, Unsaturated/*PHARMACOLOGY Human HIV-1 Reverse Transcriptase/METABOLISM Kinetics Linoleic Acid/PHARMACOLOGY Rats Recombinant Proteins/ANTAGONISTS & INHIB/METABOLISM Reverse Transcriptase Inhibitors Structure-Activity Relationship Support, Non-U.S. Gov't Thymus Gland/ENZYMOLOGY JOURNAL ARTICLE
980228
M9820697

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .